New & Notable
Lilly aligns with Walmart in bid to broaden access to discounted Zepbound
The new deal lets patients pick up online orders of Zepbound at Walmart pharmacies, expanding Eli Lilly's direct-to-consumer services.
— Biopharma Dive
Innovent, Lilly's mazdutide outdoes Novo's semaglutide in phase 3 trial
Innovent Biologics and Eli Lilly's dual GLP-1/glucagon agonist, mazdutide, beats Novo Nordisk's semaglutide in a phase 3 trial of adults with diabetes and obesity.
Report: Bipartisan support for patent reform to lower drug prices
Four in five Americans support changing patent laws to lower drug costs, favoring patent reform over government price controls by 15 points, says a new I-MAK report.
Report: Compounded GLP-1 drugs pose safety, quality risks
Compounded GLP-1 drugs pose safety and quality risks, a recent report says, adding to the growing calls for tougher regulatory enforcement.
Healthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
Report: Up to 60% of clinical trials don't survive their first year
Between 45% and 60% of new U.S. clinical trial sites shut down within one year, but trial volume and government funding can increase longevity, new research says.
-
How TrumpRx could affect PBMs, specialty pharmacies, biotech
TrumpRx's transparent cash pricing could disrupt PBM rebate models, specialty pharmacy contracts and biotech's commercialization approaches, depending on uptake, experts say.
-
Trump's 100% tariff on branded drug imports spares Big Pharma
Trump's 100% tariff on branded drug imports favors pharma giants building in America, leaving small companies without U.S. manufacturing sites or expansion plans vulnerable.
-
ACIP vaccine votes break with evidence-based policy
The CDC's advisory committee votes to scale back COVID-19 vaccine recommendations for seniors and limit MMRV in children under 4, breaking with decades of evidence-based policy.
-
FDA cracks down on online advertising of compounded GLP-1 drugs
More than 50 digital health providers were sent FDA warning letters for falsely advertising compounded GLP-1 drugs. Now, companies must update product information or face legal action.
-
Generic, biosimilar markets at risk despite saving $467B in 2024
Generics and biosimilars cut U.S. drug costs by $467B in 2024, but the AAM warns that PBMs, IRA rules and a lack of competition threaten long-term stability of the market.
Features
-
Blurring the line between GLP-1 compounders, counterfeiters
Weak regulatory oversight has allowed 503A compounding facilities to abuse customization rules, blurring the line between GLP-1 compounders and unregulated drug manufacturers.
-
Expanding clinical trial access through technology, support
Systemic barriers continue to restrict clinical trial access, but when deployed correctly, technology can provide patient–provider support and close interoperability gaps.
-
Will the FDA's green list end illegal GLP-1 compounding?
The FDA recently created a green list to regulate imported GLP-1 drug ingredients, yet experts say that weak enforcement could allow illegal compounding operations to continue.
-
Using AI to identify, expose online drug counterfeiters
Pharmaceutical companies are leveraging AI's advanced detection and enforcement tools to combat the online counterfeit drug market, protecting brand integrity and consumer safety.